Back to results
US 2026/0217829 A1Published application
Modification of anti-pd-1 antibodies to treat cancer
AssigneeThe Trustees of Columbia University in the City of New York
InventorsAdam MOR, Ruijiang SONG
Life of this patent
Estimating the term…
Abstract
The subject matter described here relates to anti-PD-1 monoclonal antibodies with increased size that are capable of modulating T-cell activity. In certain embodiments the monoclonal antibody comprises an additional Fc domain or CD22 domain.
Claims74
A monoclonal antibody or a fragment thereof, comprising:
- a first arm comprising a first variable heavy chain domain and a first variable light chain domain, wherein a portion of the first arm is capable of binding to a portion of a PD-1 protein;
- and
- a second arm comprising a second variable heavy chain domain and a second variable light chain domain, wherein a portion of the second arm is capable of binding to a portion of the PD-1 protein,
- wherein the first arm and the second arm each further comprise a first fragment crystallizable (Fc) domain,
- wherein the first arm and the second arm each further comprise at least one additional domain.
2 more elements
A means for binding a portion of a PD-1 protein.
Dependencies are inferred from the claim text.